Concepedia

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn,

Cancer Research · 2023 · 32 citations · 40 references

DOIFull text

Open access

Abstract

The bifunctional mAb fusion design of BCA101 targets it to the tumor microenvironment where it inhibits EGFR and neutralizes TGFβ to induce immune activation and to suppress tumor growth.

References

40

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

Dori A. Thomas, Joan Massagué · Cancer Cell · 2005 · 1.3K citations · Full text

, , +9

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

Jan B. Vermorken, José Trigo, Ricardo Hitt et al. · Journal of Clinical Oncology · 2007 · 996 citations · Full text

Transforming Growth Factor-α: a More Potent Angiogenic Mediator than Epidermal Growth Factor

Alain B. Schreiber, Marjorie E. Winkler, Rik Derynck · Science · 1986 · 846 citations

, , +16